AU8516982A - Antiobesity agent - Google Patents

Antiobesity agent

Info

Publication number
AU8516982A
AU8516982A AU85169/82A AU8516982A AU8516982A AU 8516982 A AU8516982 A AU 8516982A AU 85169/82 A AU85169/82 A AU 85169/82A AU 8516982 A AU8516982 A AU 8516982A AU 8516982 A AU8516982 A AU 8516982A
Authority
AU
Australia
Prior art keywords
antiobesity agent
antiobesity
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU85169/82A
Other versions
AU558020B2 (en
Inventor
Alan Chapman White
Michael Grant Wyllie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wyeth and Brother Ltd
Original Assignee
John Wyeth and Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth and Brother Ltd filed Critical John Wyeth and Brother Ltd
Publication of AU8516982A publication Critical patent/AU8516982A/en
Application granted granted Critical
Publication of AU558020B2 publication Critical patent/AU558020B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU85169/82A 1981-07-07 1982-06-23 Antiobesity agent Ceased AU558020B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8120961 1981-07-07
GB8120961 1981-07-07

Publications (2)

Publication Number Publication Date
AU8516982A true AU8516982A (en) 1983-01-13
AU558020B2 AU558020B2 (en) 1987-01-15

Family

ID=10523079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85169/82A Ceased AU558020B2 (en) 1981-07-07 1982-06-23 Antiobesity agent

Country Status (6)

Country Link
US (1) US4451465A (en)
JP (1) JPS5815915A (en)
AU (1) AU558020B2 (en)
BE (1) BE893789A (en)
IT (1) IT1157288B (en)
ZA (1) ZA824382B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344481B1 (en) 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US7202222B2 (en) * 2003-01-06 2007-04-10 National Bioscience Corporation Methods for treatment of obesity and effective fat loss promotion
PT2316456T (en) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008106213A1 (en) * 2007-02-27 2008-09-04 Titan Pharmaceuticals, Inc. Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
JP2011521973A (en) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for treating visceral fat conditions
MA37714A1 (en) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Methods of treating overweight and obesity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2200584A1 (en) * 1971-01-11 1972-07-27 Wyeth John & Brother Ltd Imido-,pyrimido-,and diazepino-(1,2-a)indoles -antidepressants - antiinflammatories,antihistamines,and hypoglycaemics with cardiovascu
GB1366133A (en) * 1971-01-11 1974-09-11 Wyeth John & Brother Ltd Fused ring indole derivatives
US4307234A (en) * 1978-09-11 1981-12-22 American Home Products Corp. Pyrimido[1,6-a]indole derivatives

Also Published As

Publication number Publication date
IT8222209A0 (en) 1982-07-02
AU558020B2 (en) 1987-01-15
JPS5815915A (en) 1983-01-29
IT1157288B (en) 1987-02-11
ZA824382B (en) 1984-02-29
BE893789A (en) 1983-01-07
US4451465A (en) 1984-05-29

Similar Documents

Publication Publication Date Title
AU551769B2 (en) Imidazodiazepines
AU551891B2 (en) Imidazodiazepines
AU561395B2 (en) 3-amino-benzazepin-2-ones
AU551756B2 (en) Imidazodiazepines
AU548397B2 (en) N-phenylsulphonyl-n:-pyrimidinyl-and-triazinyl-ureas
AU549409B2 (en) Polyetheresterimide
AU549410B2 (en) Polyetheresterimide
AU553589B2 (en) Benzoheterocycles
AU551831B2 (en) Imidazodiazepines
AU557714B2 (en) 2-arylimidazopyridines
AU547803B2 (en) s
AU583711B2 (en) 5-trifluoromethylpyridyl-2-oxyanilines
AU550571B2 (en) Co-nitration
AU546185B2 (en) Levitationarium
AU547405B2 (en) Amidobenzamides
AU564233B2 (en) N-substituted-2-pyridylindoles
AU545678B2 (en) Sleeper-tamper
AU529966B2 (en) Washer-dehydrator
AU558020B2 (en) Antiobesity agent
AU552046B2 (en) Imidazodiazepines
AU556935B2 (en) Azolyl-pentene-3-ones and -3-ols
AU565320B2 (en) Pyridobenzodiazepines
AU559489B2 (en) Bioactant translocation agent
AU555113B2 (en) Alkoxyaminohydridosilanes
AU558041B2 (en) Tetrahydronaphthoxazoles